Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dissolution is usually performed in water or a suitable aqueous buffer, and the resulting liquid is divided into single-use portions before freezing. Freeze-thaw cycling is a recognised source of loss for short peptides, since each cycle can encourage aggregation or adsorption onto container walls. Working solutions are generally kept cold and used within a short window, although published stability data specific to epitalon are thin. Containers should be marked with concentration and date, and solutions examined for cloudiness before use.
Identity is normally established by reversed-phase high-performance liquid chromatography combined with mass spectrometry, a pairing that separates components and confirms molecular mass at once. Purity is quoted as a percentage from the chromatogram, and figures above ninety-five percent are a frequent commercial specification. Amino acid analysis or sequencing supplies further confirmation when required. Because many short peptides behave similarly under chromatography, retention time alone does not establish sequence; the mass measurement is what separates one tetrapeptide from another, and certificates should report both.
Short peptides such as AEDG are normally supplied as a freeze-dried solid and are kept dry, cold, and shielded from light. Holding at minus twenty degrees Celsius is common for the long term, while a refrigerator suffices for brief periods before use. The material takes up moisture to some degree, so containers should stay sealed and be allowed to reach room temperature before opening, which limits condensation on the contents. Repeated warming and cooling of a single container is discouraged because it admits water and can lower the amount of intact peptide.
Typical storage for the lyophilized powder is −20 °C or lower, in a sealed container protected from light and moisture. Hygroscopic material should be allowed to equilibrate to room temperature before the vial is opened, which limits condensation on the contents. Working solutions are commonly divided into single-use aliquots and frozen to avoid repeated freeze-thaw cycles. Dilute solutions are more prone to adsorption onto plastic surfaces and to loss during filtration, so procedures that minimize transfers and use low-binding labware are preferable.
Reversed-phase high-performance liquid chromatography is the standard approach for assessing purity, usually with ultraviolet detection near 214 nm, where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the molecular mass and helps reveal truncation or deletion byproducts. Amino acid analysis can verify composition, and counterion content is sometimes measured because peptides purified with trifluoroacetic acid retain variable amounts of that salt. Purity figures reported without a stated method and detection wavelength are difficult to interpret.
Material sold for research use varies widely in documented quality. A useful verification package includes a certificate of analysis that states peptide content rather than only net weight, the chromatographic method and column used, and a mass spectrum consistent with the expected mass. Independent testing by a third-party laboratory is occasionally reported. Statements of identity resting only on a supplier label provide little assurance, and the gap between nominal mass and actual peptide content can be substantial once counterions and residual water are counted.
| Property | Value | Notes |
|---|---|---|
| Sequence | Ala-Glu-Asp-Gly | Written in three-letter amino acid code |
| Single-letter code | AEDG | Form used in most catalogue entries |
| Typical purity specification | 95 percent or higher | Value read from the HPLC chromatogram |
| Storage, dry solid | Minus 20 degrees Celsius, desiccated | Sealed container, protected from light |
| Handling, solution | Divide into single-use portions | Limits losses from freeze-thaw cycling |
No pharmacopoeial monograph exists for this peptide, so quality rests on the supplier's internal specifications and on whatever independent testing a purchaser arranges. Certificates of analysis differ widely in which tests they report and in the limits applied. The counter-ion introduced during purification, commonly acetate or trifluoroacetate, changes the net peptide content of a given mass of powder, so two samples of equal weight may not contain equal amounts of the active sequence. Third-party laboratories can verify purity, identity, residual solvents, and counter-ion content for a fee, which makes documentation more informative than labelling.
Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.
Identity and purity are checked by reversed-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, where the peptide bond absorbs. Mass spectrometry confirms the expected mass and reveals whether truncation products or adducts are present. Acid hydrolysis followed by amino acid analysis gives the residue ratio, which should approximate one alanine, one glutamate, one aspartate and one glycine. Counter-ions such as acetate or trifluoroacetate remain in the dried product and lower net peptide content, so a stated purity figure on a label does not by itself describe how much peptide a vial holds.
Regulatory treatment differs by country. No formulation of epitalon holds a marketing authorisation as a medicine in the United States or the European Union, where material sold for laboratory use is handled as a research chemical and is not intended for human consumption. In Russia, several short peptide preparations from the same institute's peptide series are registered medicinal products, and epitalon appears in that national context. Elsewhere it is frequently offered as a cosmetic ingredient, a category with lighter requirements. Advertising claims about longevity or disease prevention are restricted in most jurisdictions, which limits how sellers describe the compound.
Freeze-dried epitalon is normally kept at minus twenty degrees Celsius in a sealed, desiccated container, protected from light. Short excursions at ambient temperature during shipping are generally tolerated, but repeated warming and cooling cycles encourage moisture uptake, which shortens shelf life. Once dissolved, the peptide is far less stable than the solid: aqueous solutions are subject to hydrolysis and to deamidation at the aspartate and glutamate residues. Working solutions are therefore held refrigerated and used within days, and repeated freezing and thawing of the same vial is best avoided.
Storage and handling follow conventional peptide practice. Lyophilized epitalon is typically kept refrigerated or frozen, protected from moisture and light, and allowed to equilibrate to room temperature before opening to avoid condensation. Once dissolved, aqueous solutions are usually stored cold and used within a short period, since dilute peptide solutions can support microbial growth and may slowly degrade. The absence of cysteine and methionine reduces, but does not eliminate, oxidation concerns during long-term storage.
Regulatory status varies by country and is not harmonized. Epitalon is not an approved drug in major Western jurisdictions. In some countries it is sold as a research chemical, and in others it has appeared in products marketed for other categories. This inconsistent status means that purity, labeling accuracy, and documentation differ widely between suppliers, and verification of identity and purity through independent analysis is the usual way buyers assess a given lot.
Bradley Lether Pentelute (born December 5, 1977) is currently a professor of chemistry at the Massachusetts Institute of Technology (MIT). His research program lies at the intersection of chemistry and biology and develops bioconjugation strategies, cytosolic delivery platforms, and rapid flow synthesis technologies to optimize the production, achieve site-specific modification, enhance stability, and modulate function of a variety of bioactive agents. His laboratory successfully modified proteins via cysteine-containing “pi-clamps” made up of a short sequence of amino acids, and delivered large biomolecules, such as various proteins and drugs, into cells via the anthrax delivery vehicle. Pentelute has also made several key contributions to automated synthesis technologies in flow. These advances includes the invention of the world's fastest polypeptide synthesizer. This system is able to form amide bonds at a more efficient rate than standard commercial equipment and has helped in the process of understanding protein folding and its mechanisms. This automated flow technology was recently used to achieve total chemical synthesis of protein chains up to 164 amino acids in length that retained the structure and function of native variants obtained by recombinant expression. The primary goal of his endeavor is to use these processes to create designer biologics that can be used to treat diseases and solve the manufacturing problem for on-demand personalized therapies, such as cancer vaccines.
== Research == G protein-biased MOR agonists like SR-17018 have potential medical applications as analgesics in the treatment of pain and as opioid substitutes in the treatment of opioid dependence and withdrawal. However, it remains unclear whether G protein-biased MOR agonists, such as SR-17018 and oliceridine, are truly clinically advantageous to conventional MOR agonists. SR-17018 has only been assessed in preclinical research and has not been formally studied in humans. Improved analogues of SR-17018 are being studied by Laura Bohn and colleagues as of December 2025.
=== Japan === As of February 2026, 94.2% of Japan's crude oil imports came from the Middle East. However, the impacts of the oil supply disruption due to the strait closure were partly mitigated by its large stockpiles. On 16 March, the Government of Japan started releasing 80 million barrels of oil, equivalent to 15 days of domestic demand, from its strategic reserves.
Tang, Velcro, and Teflon were not spun off from technology originally developed by NASA for spaceflight, though many other products (such as memory foam and space blankets) were. The Sun is not yellow; rather, it emits light across the full spectrum of visible colors, and this combined light appears white when outside of Earth's atmosphere. Earth's atmosphere scatters shorter wavelengths of light, particularly blues and violets, more than longer wavelengths like reds and yellows, and this scattering is why the Sun appears yellow during the day or orange or red during sunrise and sunset. The scattered blue/violet light, appearing to come from all directions, is what makes the rest of the sky look blue. The Great Wall of China is not the only human-made object visible from space or from the Moon. None of the Apollo astronauts reported seeing any specific human-made object from the Moon, and even Earth-orbiting astronauts can see it only with magnification. City lights, however, are easily visible on the night side of Earth from orbit. The Big Bang model does not fully explain the origin of the universe. It does not describe how energy, time, and space were caused, but rather it describes the emergence of the present universe from an ultra-dense and high-temperature initial state.
NONMEM is a non-linear mixed-effects modeling software package developed by Stuart L. Beal and Lewis B. Sheiner in the late 1970s at University of California, San Francisco, and expanded by Robert Bauer at Icon PLC. Its name is an acronym for nonlinear mixed effects modeling but it is especially powerful in the context of population pharmacokinetics, pharmacometrics, and PK/PD models. NONMEM models are written in NMTRAN, a dedicated model specification language that is translated into FORTRAN, compiled on the fly and executed by a command-line script. Results are presented as text output files including tables. There are multiple interfaces to assist modelers with housekeeping of files, tracking of model development, goodness-of-fit evaluations and graphical output, such as PsN and xpose and Wings for NONMEM. Current version for NONMEM is 7.5.
Sources: en.wikipedia.org
The cover artwork for the album was designed by American artist Kaws, featuring his Companion character being assembled, or "sorted out", by two hands. Kaws has been a known collaborator with Clipse, having also designed the cover art for their 2009 album Til the Casket Drops. American artist Josh Sperling described his two alternate album covers as "The Cross and the Anchor. The Cross to represent sin, death and faith. The Anchor to represent strength and stability in unknown waters. Two symbols for Two brothers."
A rare development is amyloid purpura, a susceptibility to bleeding with bruising around the eyes, termed "raccoon-eyes". Amyloid purpura is caused by amyloid deposition in the blood vessels and reduced activity of thrombin and factor X, two clotting proteins that lose their function after binding with amyloid. Amyloid deposits in tissue can cause enlargement of structures. Twenty percent of people with AL amyloidosis have an enlarged tongue, that can lead to obstructive sleep apnea, difficulty swallowing, and altered taste. Tongue enlargement does not occur in ATTR or AA amyloidosis. Deposition of amyloid in the throat can cause hoarseness.
== Oxygen-17 == Oxygen-17 (17O) is the rarest of the three stable isotopes of oxygen with a low isotopic abundance of about 0.038% = 380 ppm in terrestrial water and air. Naturally 17O is primarily made by burning hydrogen into helium in the CNO cycle, making it a common isotope in the hydrogen burning zones of stars. As the only stable isotope of oxygen possessing a nuclear spin (+5⁄2) and a favorable characteristic of field-independent relaxation in liquid water, through extreme motional narrowing.17O enables NMR studies tracing oxidative metabolic pathways (i.e. conversion of 17O2 gas to metabolically produced H217O water by oxidative phosphorylation in mitochondria) at high magnetic fields. This is a necessary requirement to overcome the low SNR from low abundance, low gyromagnetic ratio and fast quadrupolar transversal relaxation in contrast to proton/hydrogen, which is the most commonly used nucleus in magnetic resonance. Water used as nuclear reactor coolant is subjected to intense neutron flux. Natural water starts out with 0.038% of 17O; heavy water starts out incidentally enriched to about 0.055% in that isotopes. Further, the neutron flux slowly converts 16O in the cooling water to 17O by neutron capture, increasing its concentration. The neutron flux slowly converts 17O (with much greater cross section) in the cooling water to carbon-14, an undesirable product that can escape to the environment:
== External links == "Glucagon Receptor Family: GLP-1". The International Union of Basic and Clinical Pharmacology, The British Pharmacological Society, The University of Edinburgh. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2007-10-25. glucagon-like+peptide+receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P43220 (Glucagon-like peptide 1 receptor) at the PDBe-KB.
The New York Times checked the logs of MagtiCom cellular network and verified that the calls were indeed made between the Roki Tunnel and Tskhinvali at the indicated timestamps. Russian Defense Ministry official General Nikolai Uvarov claimed that Russia was not expecting a Georgian attack and earlier on 7 August Russian peacekeeping forces in South Ossetia was supplied with fuel and products; however, he asserted he didn't know anything about Colonel Kazachenko. Georgia called into question this Russian assertion. Instead, Georgia argued that movements of the Russian peacekeeping battalion could take place only during daytime. The rotation required at least a month of advance warning according to a mutual agreement of 2004. According to Uvarov, the first Russian combat unit (the 135th Regiment) was ordered after the Georgian attack to pass through the Roki Tunnel around dawn on 8 August and they entered South Ossetia by 14:30 on August 8; however, the Russian battalion managed to arrive in Tskhinvali only the next evening. Georgia instead asserted that first Georgian encounter with the Russian troops took place before the dawn of August 8.
Sources: en.wikipedia.org
At temperatures greater than 44 °C (111 °F), proteins begin losing their three-dimensional shape and start breaking down. This results in cell and tissue damage. Many of the direct health effects of a burn are caused by failure of the skin to perform its normal functions, which include: protection from bacteria, skin sensation, body temperature regulation, and prevention of evaporation of the body's water. Disruption of these functions can lead to infection, loss of skin sensation, hypothermia, and hypovolemic shock via dehydration (i.e. water in the body evaporated away). Disruption of cell membranes causes cells to lose potassium to the spaces outside the cell and to take up water and sodium. In large burns (over 30% of the total body surface area), there is a significant inflammatory response. This results in increased leakage of fluid from the capillaries, and subsequent tissue edema. This causes overall blood volume loss, with the remaining blood suffering significant plasma loss, making the blood more concentrated. Poor blood flow to organs like the kidneys and gastrointestinal tract may result in kidney failure and stomach ulcers. Increased levels of catecholamines and cortisol can cause a hypermetabolic state that can last for years. This is associated with increased cardiac output, metabolism, a fast heart rate, and poor immune function.
=== Organizations === The World Health Organization Department of Food Safety and Zoonoses (FOS) provides scientific advice for organizations and the public on issues concerning the safety of food. Its mission is to lower the burden of foodborne disease, thereby strengthening the health security and sustainable development of Member States. Foodborne and waterborne diarrhoeal diseases kill an estimated 2.2 million people annually, most of whom are children. WHO works closely with the Food and Agriculture Organization of the United Nations (FAO) to address food safety issues along the entire food production chain—from production to consumption—using new methods of risk analysis. These methods provide efficient, science-based tools to improve food safety, thereby benefiting both public health and economic development.
The presidential transition period began following Trump's victory in the 2024 U.S. presidential election, though Trump had chosen Linda McMahon and Howard Lutnick to begin planning for the transition in August 2024. According to The New York Times, Trump was "superstitious" and preferred to avoid discussing the presidential transition process until after Election Day. His transition team relied on the work of the America First Policy Institute, rather than the Heritage Foundation, a conservative think tank that garnered controversy during the election for Project 2025, a set of initiatives that would reshape the federal government. By October, he had not participated in the federal presidential transition process, and he had not signed a required ethics pledge, as of November. During the transition period, Trump announced nominations for his cabinet and administration. Trump was inaugurated on January 20, 2025. He was sworn in by Chief Justice John Roberts. The inauguration occurred indoors in the Capitol Rotunda as a result of a severe cold wave.
The 2012 settlement included a criminal fine of US$242,612,800 for failing to report safety data to the FDA about Avandia (rosiglitazone), a diabetes drug approved in 1999, and a civil settlement of US$657 million for making false claims about it. The Justice Department said GSK had promoted rosiglitazone to physicians with misleading information, including that it conferred cardiovascular benefits despite an FDA-mandated label warning of cardiovascular risks. In 1999, John Buse, a diabetes specialist, told medical conferences that rosiglitazone might carry an increased risk of cardiovascular problems. GSK threatened to sue him, called his university head of department, and persuaded him to sign a retraction. GSK raised questions internally about the drug's safety in 2000, and in 2002, the company ghostwrote an article in Circulation describing a GSK funded clinical trial that suggested rosiglitazone might have a beneficial effect on cardiovascular risk. From 2001, reports began to link the thiazolidinediones (the class of drugs to which rosiglitazone belongs) to heart failure. In April that year, GSK began a six-year, open-label, randomized trial, known as RECORD, to examine rosiglitazone and cardiovascular events. Two GSK meta-analyses in 2005, and 2006, showed an increased risk of cardiovascular problems with rosiglitazone; the information was passed to the FDA and posted on the company website, but not otherwise published. By December 2006, rosiglitazone had become the top-selling diabetes drug, with annual sales of US$3.3 billion.
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography is run alongside mass spectrometry. The chromatogram separates components and gives a purity figure, while the mass spectrum confirms that the measured molecular mass matches the expected sequence. Neither measurement on its own is treated as sufficient.
Long-term holding is usually at minus twenty degrees Celsius in a sealed, desiccated container. A refrigerator is adequate for short intervals before use. Light exposure is normally avoided as well. Allowing a cold container to warm before opening reduces moisture condensation on the contents.
Repeated cycles are generally avoided. Each freeze and thaw can promote aggregation or loss of peptide to container surfaces, which reduces the amount available for later work. Dividing a solution into single-use portions at the outset is the usual way to limit this problem.
The powder is normally kept at −20 °C or below in a sealed, moisture-protected container. Letting the vial reach room temperature before opening helps prevent condensation on the contents.